Beyond this, miR-26a directly targeted CDK6 (Figure 1), and its reintroduction induced cell cycle arrest at G0/G1 phase in MM cells, as well as an upregulation of p53 and p21 expression [57]. Here, CDK6 is linked to Miyoshi myopathy.